Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.50 |
| ▸ | ADK | P55263 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19537076 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL16373988 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL1736124 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL21006387 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL17109566 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL3234238 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL3229893 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL21008034 | 0.91 | PRMT5 (0.47) | PRMT5WDR77ADKADORA2AMETTL3 | |
| Salicylic Acid SCHEMBL3238127 | 0.88 | PRMT5 (0.42) | PRMT5WDR77ADKADORA2A | |
| SCHEMBL19379664 | 0.88 | ADORA2A (0.48) | PRMT5WDR77ADKADORA2AMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |